Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CRC
Open-data reference.
16 US clinical trials · 10 currently recruiting
Active & Recent Trials
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines
NCT06445062
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines
NCT07349537
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06051695
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines
NCT07397338
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis
NCT06657222
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co.
NCT06259552
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Virginia Commonwealth University
NCT06728072
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
NCT07321106
Study to Evaluate D-1553 in Subjects With Solid Tumors
InventisBio Co.
NCT04585035
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
NCT06106308
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
NCT04868773
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
Jennerex Biotherapeutics
NCT01394939
Engaging Black Men in Colorectal Cancer Screening
Virginia Commonwealth University
NCT05980182
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jacobio Pharmaceuticals Co.
NCT05002270
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 12 |
| Phase 2 | 2 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the CRC Trial Landscape
ClinicalTrials.gov lists 16 US studies indexed under CRC, and 10 of those are currently open to recruitment — roughly 63% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for CRC shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 14 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for CRC is led by A2 Biotherapeutics with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 16 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for CRC?
PlainTrial tracks 16 US clinical trials for CRC, of which 10 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for CRC?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.